Status:
COMPLETED
Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer
Lead Sponsor:
Helsinn Therapeutics (U.S.), Inc
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.
Detailed Description
Cancer cachexia is a devastating, often late-stage complication of an underlying malignancy. Despite the significant importance of cancer-related cachexia, treatments are lacking and there are no prod...
Eligibility Criteria
Inclusion
- stage IIIB or IV NSCLC
- eligible for treatment of NSCLC with paclitaxel and carboplatin +/- bevacizumab
Exclusion
- mixed large and small cell histologies for lung cancer
- significant obesity, BMI \> 30
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT00622193
Start Date
March 1 2008
End Date
December 1 2009
Last Update
April 14 2017
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States, 72205
2
Osler Medical
Melbourne, Florida, United States, 32901
3
Augusta Oncology Associates
Augusta, Georgia, United States, 30901
4
South Georgia Medical Center
Valdosta, Georgia, United States, 31602